CSL Says CEO Paul McKenzie Will Retire
By Mike Cherney
SYDNEY--Australia-based pharmaceutical company CSL said that Chief Executive Paul McKenzie will retire after a three-year tenure.
CSL said that Gordon Naylor, a highly experienced former CSL senior executive, has been appointed as interim CEO, effective Wednesday.
CSL Chair Brian McNamee said the board and McKenzie had determined that now is the right time for new leadership to continue to drive CSL's strategic transformation and performance.
McKenzie's departure comes after CSL delayed a spinoff of its flu-vaccine unit Seqirus, which has been struggling amid declining vaccination rates in the U.S. CSL also announced layoffs last year, and its stock price has tumbled.
CSL said Naylor has served in senior leadership roles including chief financial officer and president of Seqirus.
"My immediate priority will be to work closely with the board and leadership team on executing our strategic transformation and delivering for our patients, public health and shareholders," Naylor said in a press release.
CSL is due to report earnings on Wednesday.
Write to Mike Cherney at mike.cherney@wsj.com
(END) Dow Jones Newswires
February 10, 2026 00:54 ET (05:54 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States